About Astria Therapeutics, Inc.
https://www.astriatx.comAstria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
CEO
Jill C. Milne
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-08-20 | Reverse | 1:6 |
| 2018-12-31 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 83
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Citizens Capital Markets
Market Outperform
JMP Securities
Market Perform
Cantor Fitzgerald
Neutral
HC Wainwright & Co.
Neutral
Wedbush
Neutral
Jefferies
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:6.49M
Value:$81.33M
FMR LLC
Shares:5.15M
Value:$64.63M
VESTAL POINT CAPITAL, LP
Shares:4.96M
Value:$62.15M
Summary
Showing Top 3 of 122
About Astria Therapeutics, Inc.
https://www.astriatx.comAstria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $706K ▲ | $34.81M ▼ | $-31.64M ▲ | -4.48K% ▼ | $-0.55 ▲ | $-31.64M ▲ |
| Q2-2025 | $0 | $35.82M ▼ | $-33.05M ▲ | 0% | $-0.57 ▲ | $-35.82M ▲ |
| Q1-2025 | $0 | $36.99M ▲ | $-33.71M ▼ | 0% | $-0.58 ▼ | $-36.99M ▼ |
| Q4-2024 | $0 | $29.59M ▲ | $-25.63M ▼ | 0% | $-0.45 ▼ | $-29.59M ▼ |
| Q3-2024 | $0 | $29.01M | $-24.53M | 0% | $-0.43 | $-29.01M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $227.72M ▼ | $271.87M ▼ | $38.61M ▲ | $233.25M ▼ |
| Q2-2025 | $259.18M ▼ | $281.92M ▼ | $21.41M ▲ | $260.51M ▼ |
| Q1-2025 | $295.06M ▼ | $310.39M ▼ | $21.1M ▼ | $289.29M ▼ |
| Q4-2024 | $328.13M ▼ | $342.36M ▼ | $23.1M ▲ | $319.26M ▼ |
| Q3-2024 | $344.28M | $361.64M | $19.98M | $341.65M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-31.64M ▲ | $-32.3M ▲ | $52.25M ▼ | $3K ▲ | $19.96M ▼ | $-32.3M ▲ |
| Q2-2025 | $-33.05M ▲ | $-36.06M ▼ | $57.99M ▲ | $0 | $21.93M ▲ | $-36.65M ▼ |
| Q1-2025 | $-33.71M ▼ | $-34.02M ▼ | $28.58M ▲ | $0 | $-5.43M ▲ | $-34.02M ▼ |
| Q4-2024 | $-25.63M ▼ | $-17.36M ▲ | $-3.72M ▼ | $0 ▼ | $-21.08M ▼ | $-17.36M ▲ |
| Q3-2024 | $-24.53M | $-27.96M | $6.19M | $15.3M | $-6.48M | $-27.98M |
CEO
Jill C. Milne
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-08-20 | Reverse | 1:6 |
| 2018-12-31 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 83
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Citizens Capital Markets
Market Outperform
JMP Securities
Market Perform
Cantor Fitzgerald
Neutral
HC Wainwright & Co.
Neutral
Wedbush
Neutral
Jefferies
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:6.49M
Value:$81.33M
FMR LLC
Shares:5.15M
Value:$64.63M
VESTAL POINT CAPITAL, LP
Shares:4.96M
Value:$62.15M
Summary
Showing Top 3 of 122